Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chunyan Cai, Xing Peng & Yumei Zhang. (2021) Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression. Bioengineered 12:1, pages 7007-7019.
Read now
Read now
Marcia A. Ciccone, Asaf Maoz, Jennifer K. Casabar, Hiroko Machida, Seiji Mabuchi & Koji Matsuo. (2016) Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. Expert Opinion on Investigational Drugs 25:7, pages 781-796.
Read now
Read now
Articles from other publishers (78)
Molly Morton, Meng Yao, Julia Chalif, Erika J. Lampert, Danielle Chau, Peter G. Rose, Robert Debernardo, Chad M. Michener, Roberto Vargas & Laura M. Chambers. (2023) Association of Clinical Trial Participation With Improved Overall Survival for Recurrent, Platinum-Resistant Ovarian Cancer. Obstetrics & Gynecology 142:3, pages 459-466.
Crossref
Crossref
Lei Dou, Enting Lu, Dongli Tian, Fangmei Li, Lei Deng & Yi Zhang. (2023) Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism. Journal of Translational Internal Medicine 11:2, pages 169-177.
Crossref
Crossref
Rebeca Kelly, Diego Aviles, Catriona Krisulevicz, Krystal Hunter, Lauren Krill, David Warshal & Olga Ostrovsky. (2023) The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome. Biomolecules 13:7, pages 1066.
Crossref
Crossref
Katherine I Foster, Katelyn F Handley, Deanna Glassman, Travis T Sims, Sanaz Javadi, Sarah M Palmquist, Mohammed M Saleh, Bryan M Fellman, Nicole D Fleming, Priya R Bhosale & Anil K Sood. (2023) Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. International Journal of Gynecologic Cancer 33:6, pages 937-943.
Crossref
Crossref
Zhiqin Deng & Guangyu Zhu. (2023) Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands. Current Opinion in Chemical Biology 74, pages 102303.
Crossref
Crossref
Mizuki Kanda, Satoshi Serada, Kosuke Hiramatsu, Masashi Funauchi, Kengo Obata, Satoshi Nakagawa, Tomoharu Ohkawara, Okinori Murata, Minoru Fujimoto, Fumiko Chiwaki, Hiroki Sasaki, Yutaka Ueda, Tadashi Kimura & Tetsuji Naka. (2023) Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia 35, pages 100853.
Crossref
Crossref
Siyu Chen, Yong Wu, Simin Wang, Jiangchun Wu, Xiaohua Wu & Zhong Zheng. (2022) A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. Journal of Ovarian Research 15:1.
Crossref
Crossref
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Tanya Jindal, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Jonathan L. Wright, Evan Y. Yu, Robert Bruce Montgomery, Andrew C. Hsieh, Petros Grivas & Ali Raza Khaki. (2022) Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer 20:6, pages 558-567.
Crossref
Crossref
Yu-An Chen, Chen-Yu Lu, Wen-Fang Cheng, Kuan-Ting Kuo, Chen-Wei Yu, Hon-Nerng Ho, Hsin-Fu Chen & Szu-Hua Pan. (2022) An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids. BMC Cancer 22:1.
Crossref
Crossref
Mahalaxmi Iyer, Anila Venugopal, Mamatha Chandrasekhar, Atchaya Suriyanarayanan, Kiruthika Balasubramani, Anand Sinthai Ilangovan, S. Kamalakannan, Rupa Gunaseelan, Niraikulam Ayyadurai, Abilash Valsala Gopalakrishnan, Lohita Rachaiah Balraj, Immanuel Aghil, Sivaprakash Palanisamy, Balachandar Vellingiri & Arul Narayanasamy. (2022) Electrical based cancer therapy for solid tumours - Theranostics approach. Biosensors and Bioelectronics: X 11, pages 100214.
Crossref
Crossref
Corinne A. Calo, Brentley Q. Smith, Kalpana Deepa Priya Dorayappan, Uksha Saini, Michelle Lightfoot, Vincent Wagner, Deepika Kalaiyarasan, Casey Cosgrove, Qi-En Wang, G. Larry Maxwell, Tamás Kálai, Periannan Kuppusamy, David E. Cohn & Karuppaiyah Selvendiran. (2022) Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. Gynecologic Oncology 164:1, pages 136-145.
Crossref
Crossref
David W. Chan, Wai-Yip Lam, Fushun Chen, Mingo M. H. Yung, Yau-Sang Chan, Wai-Sun Chan, Fangfang He, Stephanie S. Liu, Karen K. L. Chan, Benjamin Li & Hextan Y. S. Ngan. (2021) Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clinical Epigenetics 13:1.
Crossref
Crossref
Dongqing Huang, Shrabanti Chowdhury, Hong Wang, Sara R. Savage, Richard G. Ivey, Jacob J. Kennedy, Jeffrey R. Whiteaker, Chenwei Lin, Xiaonan Hou, Ann L. Oberg, Melissa C. Larson, Najmeh Eskandari, Davide A. Delisi, Saverio Gentile, Catherine J. Huntoon, Uliana J. Voytovich, Zahra J. Shire, Qing Yu, Steven P. Gygi, Andrew N. Hoofnagle, Zachary T. Herbert, Travis D. Lorentzen, Anna Calinawan, Larry M. Karnitz, S. John Weroha, Scott H. Kaufmann, Bing Zhang, Pei Wang, Michael J. Birrer & Amanda G. Paulovich. (2021) Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine 2:12, pages 100471.
Crossref
Crossref
Fabrizio Fontana, Monica Marzagalli, Michela Raimondi, Valentina Zuco, Nadia Zaffaroni & Patrizia Limonta. (2021) δ‐Tocotrienol sensitizes and re‐sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK‐mediated apoptosis. Cell Proliferation 54:11.
Crossref
Crossref
Mayu Shiomi, Shinya Matsuzaki, Satoshi Serada, Koji Matsuo, Chihiro Mizuta‐Odani, Mariko Jitsumori, Ruriko Nakae, Satoko Matsuzaki, Satoshi Nakagawa, Kosuke Hiramatsu, Ai Miyoshi, Eiji Kobayashi, Toshihiro Kimura, Yutaka Ueda, Kiyoshi Yoshino, Tetsuji Naka & Tadashi Kimura. (2021) CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Science 112:9, pages 3655-3668.
Crossref
Crossref
Mingyuan Zou, Yue Du, Ruizhen Liu, Zeliang Zheng & Jian Xu. (2021)
Nanocarrier‐delivered small interfering
RNA
for chemoresistant ovarian cancer therapy
. WIREs RNA 12:5.
Crossref
Crossref
Suresh Chava, Suresh Bugide, Yvonne J. K. Edwards & Romi Gupta. (2021) Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis 10:7.
Crossref
Crossref
Katrine Dam Olesen, Anja Tolstrup Rædkjær Larsen, Lars Henrik Jensen, Karina Dahl Steffensen & Stine Rauff Søndergaard. (2021) Treosulfan in platinum-resistant ovarian cancer. International Journal of Gynecologic Cancer 31:7, pages 1045-1051.
Crossref
Crossref
Dengxuan Fan, Hailing Yang, Weiqun Mao, Philip J. Rask, Lan Pang, Congjian Xu, Hariprasad Vankayalapat, Ahmed A. Ahmed, Robert C. BastJr.Jr. & Zhen Lu. (2021) A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers 13:3, pages 446.
Crossref
Crossref
Courtney Griffiths, Michelle Bilbao, Lauren Krill & Olga Ostrovsky. 2021. Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]. Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title].
Shelvin Kumar Vadi & Bhagwant Rai Mittal. 2021. Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology. Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology
297
332
.
Randall T. Mertens, Sean Parkin & Samuel G. Awuah. (2020)
Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(
iii
) dithiocarbamates
. Chemical Science 11:38, pages 10465-10482.
Crossref
Crossref
Ariane T. Mbemi, Jennifer N. Sims, Clement G. Yedjou, Felicite K. Noubissi, Christian R. Gomez & Paul B. Tchounwou. (2020) Vernonia calvoana Shows Promise towards the Treatment of Ovarian Cancer. International Journal of Molecular Sciences 21:12, pages 4429.
Crossref
Crossref
Tova M. Bergsten, Joanna E. Burdette & Matthew Dean. (2020) Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications. Cancer Letters 476, pages 152-160.
Crossref
Crossref
Brian Kawahara, Suvajit Sen & Pradip K Mascharak. (2020) Reaction of carbon monoxide with cystathionine β-synthase: implications on drug efficacies in cancer chemotherapy. Future Medicinal Chemistry 12:4, pages 325-337.
Crossref
Crossref
Alex R. Straughn & Sham S. Kakar. (2019) Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling. Journal of Ovarian Research 12:1.
Crossref
Crossref
Rositsa Mihaylova, Anife Ahmedova, Denitsa Momekova, Georgi Momekov & Nikolay Danchev. (2019) Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines. Investigational New Drugs 37:6, pages 1117-1126.
Crossref
Crossref
Byungji Kim, Si Sun, Judith A. Varner, Stephen B. Howell, Erkki Ruoslahti & Michael J. Sailor. (2019) Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide‐Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA. Advanced Materials 31:35, pages 1902952.
Crossref
Crossref
Alessandro Bertucci, Kang-Hoon Kim, Jinyoung Kang, Jonathan M. Zuidema, Seo Hyeon Lee, Ester J. Kwon, Dokyoung Kim, Stephen B. Howell, Francesco Ricci, Erkki Ruoslahti, Hyeung-Jin Jang & Michael J. Sailor. (2019) Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. ACS Applied Materials & Interfaces 11:27, pages 23926-23937.
Crossref
Crossref
Erin A. Blake, Chrystal A. Bradley, Sayedamin Mostofizadeh, Franco M. Muggia, Agustin A. Garcia, Lynda D. Roman & Koji Matsuo. (2019) Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Archives of Gynecology and Obstetrics 299:6, pages 1641-1649.
Crossref
Crossref
Yu-Fang Huang, Macus Tien Kuo, Yi-Sheng Liu, Ya-Min Cheng, Pei-Ying Wu & Cheng-Yang Chou. (2019) A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. Frontiers in Oncology 9.
Crossref
Crossref
Yeon Kyu Lee, Jinyeong Lim, So Young Yoon, Jong Cheon Joo, Soo Jung Park & Yoon Jung Park. (2019) Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation. International Journal of Molecular Sciences 20:10, pages 2443.
Crossref
Crossref
John Syrios, Charalambos Kouroussis, Athanasios Kotsakis, Nikolaos Kentepozidis, Emmanouil Kontopodis, Kostas Kalbakis, Nikolaos Vardakis, Dora Hatzidaki, Aris Polyzos & Vassilis Georgoulias. (2019) Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Minerva Ginecologica 71:3.
Crossref
Crossref
Koji Matsuo, Samantha E. Spragg, Marcia A. Ciccone, Erin A. Blake, Charité Ricker, Huyen Q. Pham & Lynda D. Roman. (2018) Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecologic Oncology Reports 25, pages 98-101.
Crossref
Crossref
Rohan Parikh, Samantha K. Kurosky, Margarita Udall, Jane Chang, Joseph C. Cappelleri, Jim P. Doherty & James A. Kaye. (2018) Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer 28:4, pages 738-748.
Crossref
Crossref
Madushka Y. De Zoysa, Nicole A. Nakamaru, Samantha B. Kaiser, Marcia A. Ciccone, Laila I. Muderspach & Koji Matsuo. (2018) Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report. Gynecologic Oncology Reports 23, pages 7-9.
Crossref
Crossref
Joseph W Po, Aflah Roohullah, David Lynch, Anna DeFazio, Michelle Harrison, Paul R Harnett, Catherine Kennedy, Paul de Souza & Therese M Becker. (2018) Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. Journal of Circulating Biomarkers 7, pages 184945441878261.
Crossref
Crossref
Vijayalakshmi N. Ayyagari, Tsung-han Jeff Hsieh, Paula L. Diaz-Sylvester & Laurent Brard. (2017) Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer 17:1.
Crossref
Crossref
Koji Matsuo, Malcolm S. Ross, Mayu Yunokawa, Marian S. Johnson, Hiroko Machida, Kohei Omatsu, Merieme M. Klobocista, Dwight D. Im, Shinya Satoh, Tsukasa Baba, Yuji Ikeda, Stephen H. Bush, Kosei Hasegawa, Erin A. Blake, Munetaka Takekuma, Masako Shida, Masato Nishimura, Sosuke Adachi, Tanja Pejovic, Satoshi Takeuchi, Takuhei Yokoyama, Yutaka Ueda, Keita Iwasaki, Takahito M. Miyake, Shiori Yanai, Tadayoshi Nagano, Tadao Takano, Mian M.K. Shahzad, Frederick R. Ueland, Joseph L. Kelley & Lynda D. Roman. (2017) Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecologic Oncology 147:3, pages 565-571.
Crossref
Crossref
Francesca Pistollato, Ruben Calderón Iglesias, Roberto Ruiz, Silvia Aparicio, Jorge Crespo, Luis Dzul Lopez, Francesca Giampieri & Maurizio Battino. (2017) The use of natural compounds for the targeting and chemoprevention of ovarian cancer. Cancer Letters 411, pages 191-200.
Crossref
Crossref
Kiyoshi Yoshino, Shoji Kamiura, Takeshi Yokoi, Ruriko Nakae, Masami Fujita, Masahiko Takemura, Kazushige Adachi, Akinori Wakimoto, Takamichi Nishizaki, Yasuhiko Shiki, Tateki Tsutsui, Yuki Kanda, Eiji Kobayashi, Kae Hashimoto, Seiji Mabuchi, Yutaka Ueda, Kenjiro Sawada, Takuji Tomimatsu & Tadashi Kimura. (2017) Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemotherapy and Pharmacology 80:6, pages 1239-1247.
Crossref
Crossref
Kelsey Carter, Pranela Rameshwar, Mariusz Z. Ratajczak & Sham S. Kakar. (2017) Verrucarin J inhibits ovarian cancer and targets cancer stem cells. Oncotarget 8:54, pages 92743-92756.
Crossref
Crossref
Zhen-Ning Lu, Bing Tian & Xiu-Li Guo. (2017) Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemotherapy and Pharmacology 80:5, pages 925-937.
Crossref
Crossref
Sham S. Kakar, Seema Parte, Kelsey Carter, Irving G. Joshua, Christopher Worth, Pranela Rameshwar & Mariusz Z. Ratajczak. (2017) Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget 8:43, pages 74494-74505.
Crossref
Crossref
Cody P. Coyne & Lakshmi Narayanan. (2017)
Gemcitabine-(
5′-phosphoramidate
)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)
. Chemical Biology & Drug Design 89:3, pages 379-399.
Crossref
Crossref
Fei Wang, Xuelian Du, Xiaoxia Li, Naifu Liu, Hao Yu & Xiugui Sheng. (2016) Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer. Medicine 95:51, pages e5696.
Crossref
Crossref
Qi-Rui Fu, Wei Song, Yi-Tao Deng, Hua-Liang Li, Xiao-Mei Mao, Chen-Lu Lin, Ya-Hui Zheng, Shu-Ming Chen, Qiong-Hua Chen & Qing-Xi Chen. (2016) ESC-3 induces apoptosis of human ovarian carcinomas through Wnt/β-catenin and Notch signaling in vitro and in vivo. International Journal of Oncology.
Crossref
Crossref
Mohamed Elshebeiny & Walid Almorsy. (2016) Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy. Journal of the Egyptian National Cancer Institute 28:3, pages 183-189.
Crossref
Crossref
Jessica Erriquez, Martina Olivero, Gloria Mittica, Maria Stella Scalzo, Marco Vaira, Michele De Simone, Riccardo Ponzone, Dionyssios Katsaros, Massimo Aglietta, Raffaele Calogero, Maria Flavia Di Renzo & Giorgio Valabrega. (2016) Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget 7:18, pages 26181-26191.
Crossref
Crossref
Ikuko Sawada, Kae Hashimoto, Kenjiro Sawada, Yasuto Kinose, Koji Nakamura, Aska Toda, Erika Nakatsuka, Akihiko Yoshimura, Seiji Mabuchi, Tomoyuki Fujikawa, Akiko Itai & Tadashi Kimura. (2016) The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice. International Journal of Gynecologic Cancer 26:4, pages 610-618.
Crossref
Crossref
Natividad Gomez-Roman, Neha Mohan Sahasrabudhe, Fiona McGregor, Anthony J. Chalmers, Jim Cassidy & Jane Plumb. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget 7:16, pages 22650-22664.
Crossref
Crossref
Jing Li, Siqin Yang, Ning Su, Yuan Wang, Jinjin Yu, Haifeng Qiu & Xiaoying He. (2015) Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. Tumor Biology 37:2, pages 2057-2065.
Crossref
Crossref
Lili Zhang, Jing Su, Qi Xie, Linchuan Zeng, Yan Wang, Dan Yi, Yang Yu, Shibing Liu, Songyan Li & Ye Xu. (2015)
2-Deoxy-
d
-Glucose Sensitizes Human Ovarian Cancer Cells to Cisplatin by Increasing ER Stress and Decreasing ATP Stores in Acidic Vesicles
. Journal of Biochemical and Molecular Toxicology 29:12, pages 572-578.
Crossref
Crossref
Ying-Cheng Chiang, Han-Wei Lin, Chi-Fang Chang, Ming-Cheng Chang, Chi-Feng Fu, Tsung-Ching Chen, Shu-Feng Hsieh, Chi-An Chen & Wen-Fang Cheng. (2015) Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget 6:37, pages 39740-39755.
Crossref
Crossref
Yoo-Young Lee, Hye-Kyung Jeon, Ji Eun Hong, Young Jae Cho, Ji Yoon Ryu, Jung-Joo Choi, Sang Hoon Lee, Gun Yoon, Woo Young Kim, In-Gu Do, Min Kyu Kim, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae & Byoung-Gie Kim. (2015) Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget 6:33, pages 35040-35050.
Crossref
Crossref
J. Erriquez, P. Becco, M. Olivero, R. Ponzone, F. Maggiorotto, A. Ferrero, M.S. Scalzo, E.M. Canuto, A. Sapino, L. Verdun di Cantogno, P. Bruna, M. Aglietta, M.F. Di Renzo & G. Valabrega. (2015) TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. Gynecologic Oncology 138:3, pages 627-633.
Crossref
Crossref
B T Paul, Z Blanchard, M Ridgway & W M ElShamy. (2014) BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene 34:23, pages 3036-3052.
Crossref
Crossref
Jens C. Hahne, Antje Kurz, Susanne R. Meyer, Johannes Dietl, Jörg B. Engel & Arnd Honig. (2014) Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. Archives of Gynecology and Obstetrics 291:1, pages 131-141.
Crossref
Crossref
Ethan Sagher, Lidia Hernandez, Callee Heywood, Gary T Pauly, Matthew R Young, Joel Schneider, Nancy H Colburn & Christina M Annunziata. (2014) The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells. Cancer Cell International 14:1.
Crossref
Crossref
Sham S. Kakar, Mariusz Z. Ratajczak, Karen S. Powell, Mana Moghadamfalahi, Donald M. Miller, Surinder K. Batra & Sanjay K. Singh. (2014) Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells. PLoS ONE 9:9, pages e107596.
Crossref
Crossref
Koji Matsuo, Todd B. Sheridan, Seiji Mabuchi, Kiyoshi Yoshino, Kosei Hasegawa, Kimberley D. Studeman, Dwight D. Im, Neil B. Rosenshein, Lynda D. Roman & Anil K. Sood. (2014) Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology 133:3, pages 473-479.
Crossref
Crossref
Siqing Fu, Ming-Mo Hou, Jennifer Wheler, David Hong, Aung Naing, Apostolia Tsimberidou, Filip Janku, Ralph Zinner, Sarina Piha-Paul, Gerald Falchook, Macus Tien Kuo & Razelle Kurzrock. (2013) Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Investigational New Drugs 32:3, pages 465-472.
Crossref
Crossref
Koji Matsuo, Kiyoshi Yoshino, Kosuke Hiramatsu, Chiaki Banzai, Kosei Hasegawa, Masanori Yasuda, Masato Nishimura, Todd B. Sheridan, Yuji Ikeda, Yasuhiko Shiki, Seiji Mabuchi, Takayuki Enomoto, Tadashi Kimura, Keiichi Fujiwara, Lynda D. Roman & Anil K. Sood. (2014) Effect of Lymphovascular Space Invasion on Survival of Stage I Epithelial Ovarian Cancer. Obstetrics & Gynecology 123:5, pages 957-965.
Crossref
Crossref
Kyung Eun Choi, Young Suk Jung, Dea Hwan Kim, Ju Kyung Song, Ji Young Kim, Yu Yeon Jung, So Young Eum, Joo Hwan Kim, Na Young Yoon, Hwan Soo Yoo, Sang-Bae Han & Jin Tae Hong. (2014) Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway. Archives of Pharmacal Research 37:4, pages 501-511.
Crossref
Crossref
Koji Matsuo, Masato Nishimura, Kakajan Komurov, Mian M.K. Shahzad, Rouba Ali-Fehmi, Ju-Won Roh, Chunhua Lu, Dianna D. Cody, Prahlad T. Ram, Nick Loizos, Robert L. Coleman & Anil K. Sood. (2014) Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecologic Oncology 132:1, pages 166-175.
Crossref
Crossref
Patrizia Vici, Domenico Sergi, Laura Pizzuti, Luciano Mariani, Maria Grazia Arena, Maddalena Barba, Marcello Maugeri-Saccà, Cristina Vincenzoni, Enrico Vizza, Giacomo Corrado, Giancarlo Paoletti, Federica Tomao, Silverio Tomao, Diana Giannarelli & Luigi Di Lauro. (2013) Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. Journal of Experimental & Clinical Cancer Research 32:1.
Crossref
Crossref
Lisa Yu, Yan Zhao, Chao Quan, Wei Ji, Jing Zhu, Yun Huang, Rongwei Guan, Donglin Sun, Yan Jin, Xiangning Meng, Chunyu Zhang, Yang Yu, Jing Bai, Wenjing Sun & Songbin Fu. (2013) Gemcitabine Eliminates Double Minute Chromosomes from Human Ovarian Cancer Cells. PLoS ONE 8:8, pages e71988.
Crossref
Crossref
QIUYI XU, NONG XU, WEIJIA FANG, PENG ZHAO, CHENYU MAO, YULONG ZHENG & HAIBO MOU. (2013) Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature. Oncology Letters 5:5, pages 1601-1604.
Crossref
Crossref
JENS C. HAHNE, SUSANNE R. MEYER, STEPAN GAMBARYAN, ULRICH WALTER, JOHANNES DIETL, JÖRG B. ENGEL & ARND HONIG. (2013) Immune escape of AKT overexpressing ovarian cancer cells. International Journal of Oncology 42:5, pages 1630-1635.
Crossref
Crossref
J.C. HAHNE, A. HONIG, S.R. MEYER, S. GAMBARYAN, U. WALTER, J. WISCHHUSEN, S.F.M. HÄUSSLER, S.E. SEGERER, N. FUJITA, J. DIETL & J.B. ENGEL. (2012) Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncology Reports 28:6, pages 2023-2028.
Crossref
Crossref
Koji Matsuo, Erin A. Blake, Annie A. Yessaian & Lynda D. Roman. (2012) Long-Term Pegylated Liposomal Doxorubicin Use and Oromaxillary Squamous Cell Carcinoma in Endometrial Cancer. The Oncologist 17:12, pages 1598-1599.
Crossref
Crossref
Ayako Kim, Yutaka Ueda, Tetsuji Naka & Takayuki Enomoto. (2012) Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 31:1.
Crossref
Crossref
Sham S. Kakar, Venkatakrishna R. Jala & Miranda Y. Fong. (2012) Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. Biochemical and Biophysical Research Communications 423:4, pages 819-825.
Crossref
Crossref
Siqing Fu, Aung Naing, Caroline Fu, Macus Tien Kuo & Razelle Kurzrock. (2012) Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent. Molecular Cancer Therapeutics 11:6, pages 1221-1225.
Crossref
Crossref
Koji Matsuo, Christina P. Prather, Edward H. Ahn, Michele L. Eno, Katherine E. Tierney, Annie A. Yessaian, Dwight D. Im, Neil B. Rosenshein & Lynda D. Roman. (2012) Significance of Perioperative Infection in Survival of Patients With Ovarian Cancer. International Journal of Gynecological Cancer 22:2, pages 245-253.
Crossref
Crossref
S McMeekin, R Patel, C Verschraegen, P Celano, J Burke, S Plaxe, P Ghatage, M Giurescu, C Stredder, Y Wang & T Schmelter. (2011) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. British Journal of Cancer 106:1, pages 70-76.
Crossref
Crossref
Koji Matsuo, Edward H. Ahn, Christina P. Prather, Michele L. Eno, Dwight D. Im & Neil B. Rosenshein. (2011) Patient-Reported Symptoms and Survival in Ovarian Cancer. International Journal of Gynecological Cancer 21:9, pages 1555-1565.
Crossref
Crossref
Koji Matsuo, Masato Nishimura, Justin N. Bottsford-Miller, Jie Huang, Kakajan Komurov, Guillermo N. Armaiz-Pena, Mian M.K. Shahzad, Rebecca L. Stone, Ju Won Roh, Angela M. Sanguino, Chunhua Lu, Dwight D. Im, Neil B. Rosenshien, Atsuko Sakakibara, Tadayoshi Nagano, Masato Yamasaki, Takayuki Enomoto, Tadashi Kimura, Prahlad T. Ram, Kathleen M. Schmeler, Gary E. Gallick, Kwong K. Wong, Michael Frumovitz & Anil K. Sood. (2011) Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research 17:16, pages 5367-5378.
Crossref
Crossref